Fig. 4. Biological Parametric Mapping (BPM) and Region of Interest (ROI) correlations of ¹¹C-BU99008 with ¹⁸F-FDG, VBM and ¹⁸F-Florbetaben in Aβ-positive patients (N = 7).

a BPM: Reduced ¹¹C-BU99008 uptake correlated with reduced ¹⁸F-FDG uptake, rendered at cluster threshold of p < 0.01. b ROI: ¹¹C-BU99008 uptake positively correlated with ¹⁸F-FDG uptake in the temporal (r = 0.567) and parietal (r = 0.623) lobes, although these did not reach significance (p = 0.184 and p = 0.135, respectively). c BPM: Reduced ¹¹C-BU99008 uptake correlated with reduced GM volume, shown through sections at cluster threshold of p < 0.01. d ROI: ¹¹C-BU99008 uptake positively correlated with GM volume in the temporal (r = 0.935, p = 0.002) and parietal (r = 0.833, p = 0.02) lobes. e BPM: Increased ¹⁸F-florbetaben uptake correlated with reduced ¹¹C-BU99008 uptake, rendered at cluster threshold of p < 0.05. f ROI: ¹¹C-BU99008 uptake positively correlated with ¹⁸F-florbetaben uptake in the temporal (r = 0.779) and parietal (r = 0.471) lobes, although only the temporal lobe reached significance (p = 0.039 and p = 0.287, respectively). g BPM: Increased ¹⁸F-florbetaben uptake correlated with increased ¹¹C-BU99008 uptake, rendered at cluster threshold of p < 0.05. Colourbar units in (a), (c), (e), and (g) are contrast estimates representative of Z-scores. All BPM correlations are displayed with an extent threshold of 50 voxels. Multiple comparison corrections were not performed on the BPM results due to the exploratory nature of this pilot study.